Cardiology

From measles resurgence to new CVD guidelines, refresh your memory of this year’s highlights with our quiz on the most-read content on Patient Care®.

When CKD 4-5 progresses to ESRD, how should hypertension management be changed? Or, should it?

ICYMI: Get a quick look at 12 of the many drugs FDA-approved in 2019 for conditions commonly seen in primary care.

Depression & anxiety in COPD patients respond well to pulmonary rehabilitation but how to proceed safely in patients with comorbid CVD?

AHA 2019 ICYMI: Summaries of 11 late-breaking clinical trials presented at the 2019 Scientific Sessions held in Philadelphia, PA, Nov 16-18.

AHA Scientific Sessions 2019: In SIHD patients with moderate-severe ischemia, initial revascularization + OMT compared to OMT alone did not reduce the risk for adverse CV outcomes

AHA Scientific Sessions 2019: Early results from the EVAPORATE study suggest promise for icosapent ethyl as add-on therapy in patients with high TGs already taking statins. 

Researchers of the new study being presented at the upcoming AHA 2019 Scientific Sessions highlight key inequalities related to disparities in the vaccination rates. 

After bariatric surgery, risk of a cerebrovascular event among obese patients was found to be signficantly lower than among matched controls. An AHA 2019 preview.

A new study being presented next week at AHA's 2019 Scientific Sessions found a strong link between depression and non-fatal heart disease. 

We preview findings of 2 studies on negative CV effects of e-cigarettes--on metabolic profiles and coronary blood flow--to be presented at the AHA 2019 Scientific Sessions next week.

Two studies to be presented at the upcoming AHA annual meeting found that young cannabis users are at greater risk for stroke and arrhythmia. 

Screening for depression among ACS patients is widely recommended by professional guidelines, but a new study suggests little return on the investment.

A single AI-enabled ECG identified AF with a sensitivity of 79%, a specificity of 79.5%, and an overall accuracy of 79.4%, according to a new study.

The European and American guidelines on dyslipidemia management overlap but also diverge in critical ways. A Johns Hopkins cardiologist highlights similarities and differences.

The SGLT-2 inhibitor canagliflozin was FDA-approved on September 30, 2019, to slow progression of diabetic kidney disease and reduce risk of heart failure hospitalization.

Take a look at the evolution of aspirin used in modern disease prevention to gain perspective on how more recent developments may affect your practice.

We take the long view on aspirin's history in this short slideshow. See how aspirin has shaped medicine from its discovery to the 18th century.

Lower bleeding rates but no increase in risk of death, MI, or stroke topped results reported from the TWIGHLIGHT study which compared ticagrelor monotherapy at 3 months post-PCI vs ticarelor plus aspirin.

Veterans who suffer from mental illness were found to be at an increased risk for major cardiovascular disease outcomes in a new study. 

Cases of infective endocarditis are on the rise and a new study suggests the opioid epidemic could be to blame. 

A recent study suggests blood pressure patterns later in life may be linked to dementia risk. Which patient cohort is at an increased risk?

What's your caffeine IQ? Test your knowledge on the latest caffeine research from its effect on cardiovascular disease to liver cancer with this brief quiz. 

A large Swedish cohort study suggests that when it come to risk of atrial fibrillation, there are differences in the way women and men respond to endurance training.

Heavy smokers who quit remain at significantly increased CVD risk for up to 10 years or more, according to new research. Results suggest that current risk estimators may need revision.